avutometinib avutometinib avutometinib (inn; codenamed ro-5126766, ch-5126766, cki-27, r-7304, rg-7304, and vs-6766 at various stages of its development) is an inhibitor of ras-raf-mek-erk signaling being developed as a potential treatment for cancer. avutometinibskeletal formula and ball-and-stick model of avutometinibclinical dataother namesro-5126766; ch-5126766; cki-27; r-7304; rg-7304pharmacokinetic dataelimination half-life60 h (45.8–93.7 h)identifiers iupac name 3-methyl]-4-methyl-7-pyrimidin-2-yloxychromen-2-one cas number946128-88-7pubchem cid16719221drugbankdb15254chemspider17623621uniid0d4252v97keggd12515chebichebi:78825chemblchembl3264002pdb ligandchu (pdbe, rcsb pdb)chemical and physical dataformulac21h18fn5o5smolar mass471.46 g·mol−13d model (jsmol)interactive image smiles cc1=c(c(=o)oc2=c1c=cc(=c2)oc3=nc=cc=n3)cc4=c(c(=nc=c4)ns(=o)(=o)nc)f inchi inchi=1s/c21h18fn5o5s/c1-12-15-5-4-14(31-21-25-7-3-8-26-21)11-17(15)32-20(28)16(12)10-13-6-9-24-19(18(13)22)27-33(29,30)23-2/h3-9,11,23h,10h2,1-2h3,(h,24,27)key:lmmjfbmmjumsjs-uhfffaoysa-n it was discovered by chugai pharmaceutical co. (a subsidiary of roche) through derivatization of a hit compound identified by high-throughput screening. it was licensed by verastem oncology in 2020 for clinical trials.